Compare Natera Inc. Common Stock (NTRA) vs New York Times Co (NYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs New York Times Co — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while New York Times Co trades at $67.13 (market cap $10.83B). The key difference: Natera Inc. Common Stock is far larger — about 5.3× New York Times Co's market cap, and New York Times Co pays a 1.37% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and New York Times Co for 82 Days on average.
| NTRA | NYT | |
|---|---|---|
Market Cap | $57.03B | $10.83B |
Volume | 1,131,157 | 1,004,378 |
Sector | Health | Media |
52-Week High | $425.64 | $85.86 |
52-Week Low | $179.42 | $54.86 |
Typical Hold Time | 0 Days | 82 Days |
Enterprise Value | $56.18B | $10.22B |
Dividend Yield | — | 1.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
The New York Times Company (NYT) trades at $66.88, up 1.21% today, with a bearish technical signal but strong fundamental performance. Revenue grew to $2.82B in 2025 with a net income margin of 12.17%, and the company has beaten EPS estimates for three consecutive quarters. A recent shareholder lawsuit alleging bias in reporting and the ongoing AI copyright case with OpenAI are key news items.
The outlook is mixed: solid earnings growth and a consensus price target of $81.50 suggest upside, but legal risks and a bearish technical picture near-term pose challenges. The stock offers a dividend yield supported by positive cash flow, yet investor sentiment is cautious amid litigation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
